In Vivo Radioprotection of Mice by 3-Methyl-1-phenyl-2-pyrazolin-5-one (Edaravone; Radicut®), a Clinical Drug

• DOI: 10.1269/jrr.45.319
• Publication Date: 2004-08-10T06:06:19Z
• Authors: Kazunori ANZAI; Masako FURUSE; Akira YOSHIDA; Azusa MATSUYAMA; Takashi MORITAKE; Koji TSUBOI; Nobuo IKOTA
• Keywords: Edaravone

Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one; Radicut) is a brain-protecting agent used clinically to treat acute ischemic stroke with reaction mechanism of free radical scavenging. Since the initial stage radiation damage involves formation radicals, edaravone expected be effective in preventing lethal from ionizing radiation. In present study, we mice examine vivo radioprotective effect on whole body X-ray irradiation. A solution was administered intraperitoneally C3H (male, 10 weeks old), and they were irradiated total dose 8.0 Gy. exhibited dose-dependent injection time-dependent radioprotection. When injected 30 min before irradiation, it had greatest effect, whereas an after irradiation showed no protective effect. The LD(50/30) about 8.8 Gy for edaravone-injected 6.6 control mice, yielding DRF (450 mg/kg bw) 1.3. decreased temperature transiently 3-6C, but this did not seem responsible radioprotection observed only when reagent primary action might quenching radicals short lifetime generated by